Substantia nigra

Substantia nigra
Substantia nigra highlighted in red.
Section through superior colliculus showing substantia nigra.
Details
Part ofMidbrain, basal ganglia
Identifiers
Latinsubstantia nigra
Acronym(s)SN
MeSHD013378
NeuroNames536
NeuroLex IDbirnlex_789
TA98A14.1.06.111
TA25881
FMA67947
Anatomical terms of neuroanatomy

The substantia nigra (SN) is a basal ganglia structure located in the midbrain that plays an important role in reward and movement. Substantia nigra is Latin for "black substance", reflecting the fact that parts of the substantia nigra appear darker than neighboring areas due to high levels of neuromelanin in dopaminergic neurons.[1] Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta.[2]

Although the substantia nigra appears as a continuous band in brain sections, anatomical studies have found that it actually consists of two parts with very different connections and functions: the pars compacta (SNpc) and the pars reticulata (SNpr). The pars compacta serves mainly as a projection to the basal ganglia circuit, supplying the striatum with dopamine. The pars reticulata conveys signals from the basal ganglia to numerous other brain structures.[3]

Structure

[edit]
Coronal slices of human brain showing the basal ganglia, globus pallidus: external segment (GPe), subthalamic nucleus (STN), globus pallidus: internal segment (GPi), and substantia nigra (SN, red). The right section is the deeper one, closer to the back of the head
Diagram of the main components of the basal ganglia and their interconnections
Anatomical overview of the main circuits of the basal ganglia, substantia nigra is shown in black. Picture shows 2 coronal slices that have been superimposed to include the involved basal ganglia structures. + and – signs at the point of the arrows indicate respectively whether the pathway is excitatory or inhibitory in effect. Green arrows refer to excitatory glutamatergic pathways, red arrows refer to inhibitory GABAergic pathways and turquoise arrows refer to dopaminergic pathways that are excitatory on the direct pathway and inhibitory on the indirect pathway.
See also: Primate basal ganglia system

The substantia nigra, along with four other nuclei, is part of the basal ganglia. It is the largest nucleus in the midbrain, lying dorsal to the cerebral peduncles. Humans have two substantiae nigrae, one on each side of the midline.

The SN is divided into two parts: the pars reticulata (SNpr) and the pars compacta (SNpc), which lies medial to the pars reticulata. Sometimes, a third region, the pars lateralis, is mentioned, though it is usually classified as part of the pars reticulata. The (SNpr) and the internal globus pallidus (GPi) are separated by the internal capsule.[4]

Pars reticulata

[edit]
Main article: Pars reticulata

The pars reticulata bears a strong structural and functional resemblance to the internal part of the globus pallidus. The two are sometimes considered parts of the same structure, separated by the white matter of the internal capsule. Like those of the globus pallidus, the neurons in pars reticulata are mainly GABAergic.[5][6]

Afferent connections

[edit]

The main input to the SNpr derives from the striatum. It comes by two routes, known as the direct and indirect pathways. The direct pathway consists of axons from medium spiny cells in the striatum that project directly to pars reticulata. The indirect pathway consists of three links: a projection from striatal medium spiny cells to the external part of the globus pallidus; a GABAergic projection from the globus pallidus to the subthalamic nucleus, and a glutamatergic projection from the subthalamic nucleus to the pars reticulata.[6][7][better source needed] Thus, striatal activity via the direct pathway exerts an inhibitory effect on neurons in the (SNpr) but an excitatory effect via the indirect pathway. The direct and indirect pathways originate from different subsets of striatal medium spiny cells: They are tightly intermingled, but express different types of dopamine receptors, as well as showing other neurochemical differences.

Efferent connections

[edit]

Significant projections occur to the thalamus (ventral lateral and ventral anterior nuclei), superior colliculus, and other caudal nuclei from the pars reticulata (the nigrothalamic pathway),[8] which use GABA as their neurotransmitter. In addition, these neurons form up to five collaterals that branch within both the pars compacta and pars reticulata, likely modulating dopaminergic activity in the pars compacta.[9]

Function

[edit]

The substantia nigra is an important player in brain function, in particular, in eye movement, motor planning, reward-seeking, learning, and addiction. Many of the substantia nigra's effects are mediated through the striatum. The nigral dopaminergic input to the striatum via the nigrostriatal pathway is intimately linked with the striatum's function.[10] The co-dependence between the striatum and substantia nigra can be seen in this way: when the substantia nigra is electrically stimulated, no movement occurs; however, the symptoms of nigral degeneration due to Parkinson's is a poignant example of the substantia nigra's influence on movement. In addition to striatum-mediated functions, the substantia nigra also serves as a major source of GABAergic inhibition to various brain targets.

Pars reticulata

[edit]
Main article: Pars reticulata § Function

The pars reticulata of the substantia nigra is an important processing center in the basal ganglia. The GABAergic neurons in the pars reticulata convey the final processed signals of the basal ganglia to the thalamus and superior colliculus. In addition, the pars reticulata also inhibits dopaminergic activity in the pars compacta via axon collaterals, although the functional organization of these connections remains unclear.

The GABAergic neurons of the pars reticulata spontaneously fire action potentials. In rats, the frequency of action potentials is roughly 25 Hz.[11] The purpose of these spontaneous action potentials is to inhibit targets of the basal ganglia, and decreases in inhibition are associated with movement.[12] The subthalamic nucleus gives excitatory input that modulates the rate of firing of these spontaneous action potentials. However, lesion of the subthalamic nucleus leads to only a 20% decrease in pars reticulata firing rate, suggesting that the generation of action potentials in the pars reticulata is largely autonomous,[13] as exemplified by the pars reticulata's role in saccadic eye movement. A group of GABAergic neurons from the pars reticulata projects to the superior colliculus, exhibiting a high level of sustained inhibitory activity.[14] Projections from the caudate nucleus to the superior colliculus also modulate saccadic eye movement. Altered patterns of pars reticulata firing such as single-spike or burst firing are found in Parkinson's disease[15] and epilepsy.[16]

Pars compacta

[edit]
Main article: Pars compacta § Function

The most prominent function of the pars compacta is motor control,[17] though the substantia nigra's role in motor control is indirect; electrical stimulation of the substantia nigra does not result in movement, due to mediation of the striatum in the nigral influence of movement. The pars compacta sends excitatory input to the striatum via D1 pathway that excites and activates the striatum, resulting in the release of GABA onto the globus pallidus to inhibit its inhibitory effects on the thalamic nucleus. This causes the thalamocortical pathways to become excited and transmits motor neuron signals to the cerebral cortex to allow the initiation of movement, which is absent in Parkinson's disease. However, lack of pars compacta neurons has a large influence on movement, as evidenced by the symptoms of Parkinson's. The motor role of the pars compacta may involve fine motor control, as has been confirmed in animal models with lesions in that region.[18]

The pars compacta is heavily involved in learned responses to stimuli. In primates, dopaminergic neuron activity increases in the nigrostriatal pathway when a new stimulus is presented.[19] Dopaminergic activity decreases with repeated stimulus presentation.[19] However, behaviorally significant stimulus presentation (i.e. rewards) continues to activate dopaminergic neurons in the substantia nigra pars compacta. Dopaminergic projections from the ventral tegmental area (bottom part of the "midbrain" or mesencephalon) to the prefrontal cortex (mesocortical pathway) and to the nucleus accumbens (mesolimbic pathway – "meso" referring to "from the mesencephalon"... specifically the ventral tegmental area) are implicated in reward, pleasure, and addictive behavior. The pars compacta is also important in spatial learning, the observations about one's environment and location in space. Lesions in the pars compacta lead to learning deficits in repeating identical movements,[20] and some studies point to its involvement in a dorsal striatal-dependent, response-based memory system that functions relatively independent of the hippocampus, which is traditionally believed to subserve spatial or episodic-like memory functions.[21]

The pars compacta also plays a role in temporal processing and is activated during time reproduction. Lesions in the pars compacta leads to temporal deficits.[22] As of late, the pars compacta has been suspected of regulating the sleep-wake cycle,[23] which is consistent with symptoms such as insomnia and REM sleep disturbances that are reported by patients with Parkinson's disease. Even so, partial dopamine deficits that do not affect motor control can lead to disturbances in the sleep-wake cycle, especially REM-like patterns of neural activity while awake, especially in the hippocampus.[24]

Clinical significance

[edit]

The substantia nigra is critical in the development of many diseases and syndromes, including parkinsonism and Parkinson's disease. There exists a study showing that high-frequency stimulation delivery to the left substantia nigra can induce transient acute depression symptoms.[25]

Parkinson's disease

[edit]
Substantia nigra with loss of cells and Lewy body pathology
Main article: Parkinson's disease

Parkinson's disease is a neurodegenerative disease characterized, in part, by the death of dopaminergic neurons in the SNpc. The major symptoms of Parkinson's disease include tremor, akinesia, bradykinesia, and stiffness.[26] Other symptoms include disturbances to posture, fatigue, sleep abnormalities, and depressed mood.[27]

The cause of death of dopaminergic neurons in the SNpc is unknown. However, some contributions to the unique susceptibility of dopaminergic neurons in the pars compacta have been identified. For one, dopaminergic neurons show abnormalities in mitochondrial complex 1, causing aggregation of alpha-synuclein; this can result in abnormal protein handling and neuron death.[28] Secondly, dopaminergic neurons in the pars compacta contain less calbindin than other dopaminergic neurons.[29] Calbindin is a protein involved in calcium ion transport within cells, and excess calcium in cells is toxic. The calbindin theory would explain the high cytotoxicity of Parkinson's in the substantia nigra compared to the ventral tegmental area. Regardless of the cause of neuronal death, the plasticity of the pars compacta is very robust; Parkinsonian symptoms do not generally appear until at least 30% of pars compacta dopaminergic neurons have died.[30] Most of this plasticity occurs at the neurochemical level; dopamine transport systems are slowed, allowing dopamine to linger for longer periods of time in the chemical synapses in the striatum.[31]

Menke, Jbabdi, Miller, Matthews and Zari (2010) used diffusion tensor imaging, as well as T1 mapping to assess volumetric differences in the SNpc and SNpr, in participants with Parkinson's compared to healthy individuals. These researchers found that participants with Parkinson's consistently had a smaller substantia nigra, specifically in the SNpr. Because the SNpr is connected to the posterior thalamus, ventral thalamus and specifically, the motor cortex, and because participants with Parkinson's disease report having a smaller SNprs (Menke, Jbabdi, Miller, Matthews and Zari, 2010), the small volume of this region may be responsible for motor impairments found in Parkinson's disease patients. This small volume may be responsible for weaker and/or less controlled motor movements, which may result in the tremors often experienced by those with Parkinson's.[32]

Oxidative stress and oxidative damage in the SNpc are likely key drivers in the etiology of Parkinson's disease as individuals age.[33] DNA damages caused by oxidative stress can be repaired by processes modulated by alpha-synuclein.[34] Alpha synuclein is expressed in the substantia nigra, but its DNA repair function appears to be compromised in Lewy body inclusion bearing neurons.[34] This loss may trigger cell death.[35][36][37]

Schizophrenia

[edit]
See also: Dopamine hypothesis of schizophrenia

Increased levels of dopamine have long been implicated in the development of schizophrenia.[38] However, much debate continues to this day surrounding this dopamine hypothesis of schizophrenia. Despite the controversy, dopamine antagonists remain a standard and successful treatment for schizophrenia. These antagonists include first generation (typical) antipsychotics such as butyrophenones, phenothiazines, and thioxanthenes. These drugs have largely been replaced by second-generation (atypical) antipsychotics such as clozapine and paliperidone. In general, these drugs do not act on dopamine-producing neurons themselves, but on the receptors on the post-synaptic neuron.

Other, non-pharmacological evidence in support of the dopamine hypothesis relating to the substantia nigra include structural changes in the pars compacta, such as reduction in synaptic terminal size.[39] Other changes in the substantia nigra include increased expression of NMDA receptors in the substantia nigra, and reduced dysbindin expression. Increased NMDA receptors may point to the involvement of glutamate-dopamine interactions in schizophrenia. Dysbindin, which has been (controversially) linked to schizophrenia, may regulate dopamine release, and low expression of dysbindin in the substantia nigra may be important in schizophrenia etiology.[40] Due to the changes to the substantia nigra in the schizophrenic brain, it may eventually be possible to use specific imaging techniques (such as neuromelanin-specific imaging) to detect physiological signs of schizophrenia in the substantia nigra.[41]

Wooden Chest Syndrome

[edit]

Wooden chest, also called fentanyl chest wall rigidity syndrome, is a rare side effect of synthetic opioids such as Fentanyl, Sulfentanil, Alfentanil, Remifentanil. It results in a generalised increase in skeletal muscle tone. The mechanism is thought to be via increased dopamine release and decreased GABA release in the nerves of the substantia nigra/striatum. The effect is most pronounced on the chest wall muscles and can lead to impaired ventilation. The condition is most commonly observed in anaesthesia where rapid and high doses of these drugs are given intravenously.[42][43][44]

Multiple system atrophy

[edit]

Multiple system atrophy characterized by neuronal degeneration in the striatum and substantia nigra was previously called striatonigral degeneration.

Chemical modification of the substantia nigra

[edit]

Chemical manipulation and modification of the substantia nigra is important in the fields of neuropharmacology and toxicology. Various compounds such as levodopa and MPTP are used in the treatment and study of Parkinson's disease, and many other drugs have effects on the substantia nigra.

Amphetamine and trace amines

[edit]
See also: Amphetamine and Trace amine

Studies have shown that, in certain brain regions, amphetamine and trace amines increase the concentrations of dopamine in the synaptic cleft, thereby heightening the response of the post-synaptic neuron.[45] The various mechanisms by which amphetamine and trace amines affect dopamine concentrations have been studied extensively, and are known to involve both DAT and VMAT2.[45][46][47] Amphetamine is similar in structure to dopamine and trace amines; as a consequence, it can enter the presynaptic neuron via DAT as well as by diffusing through the neural membrane directly.[45] Upon entering the presynaptic neuron, amphetamine and trace amines activate TAAR1, which, through protein kinase signaling, induces dopamine efflux, phosphorylation-dependent DAT internalization, and non-competitive reuptake inhibition.[45][48] Because of the similarity between amphetamine and trace amines, it is also a substrate for monoamine transporters; as a consequence, it (competitively) inhibits the reuptake of dopamine and other monoamines by competing with them for uptake, as well.[45]

In addition, amphetamine and trace amines are substrates for the neuronal vesicular monoamine transporter, vesicular monoamine transporter 2 (VMAT2).[47] When amphetamine is taken up by VMAT2, the vesicle releases (effluxes) dopamine molecules into the cytosol in exchange.[47]

Cocaine

[edit]
See also: Cocaine

Cocaine's mechanism of action in the human brain includes the inhibition of dopamine reuptake,[49] which accounts for cocaine's addictive properties, as dopamine is the critical neurotransmitter for reward. However, cocaine is more active in the dopaminergic neurons of the ventral tegmental area than the substantia nigra. Cocaine administration increases metabolism in the substantia nigra, which can explain the altered motor function seen in cocaine-using subjects.[50] The inhibition of dopamine reuptake by cocaine also inhibits the firing of spontaneous action potentials by the pars compacta.[51] The mechanism by which cocaine inhibits dopamine reuptake involves its binding to the dopamine transporter protein. However, studies show that cocaine can also cause a decrease in DAT mRNA levels,[52] most likely due to cocaine blocking dopamine receptors rather than direct interference with transcriptional or translational pathways.[52]

Inactivation of the substantia nigra could prove to be a possible treatment for cocaine addiction. In a study of cocaine-dependent rats, inactivation of the substantia nigra via implanted cannulae greatly reduced cocaine addiction relapse.[53]

Levodopa

[edit]
See also: Levodopa

The substantia nigra is the target of chemical therapeutics for the treatment of Parkinson's disease. Levodopa (commonly referred to as L-DOPA), the dopamine precursor, is the most commonly prescribed medication for Parkinson's disease, despite controversy concerning the neurotoxicity of dopamine and L-DOPA.[54] The drug is especially effective in treating patients in the early stages of Parkinson's, although it does lose its efficacy over time.[55] Levodopa can cross the blood–brain barrier and increases dopamine levels in the substantia nigra, thus alleviating the symptoms of Parkinson's disease. The drawback of levodopa treatment is that it treats the symptoms of Parkinson's (low dopamine levels), rather than the cause (the death of dopaminergic neurons in the substantia nigra).

MPTP

[edit]
See also: MPTP

MPTP, is a neurotoxin specific to dopaminergic cells in the brain, specifically in the substantia nigra. MPTP was brought to the spotlight in 1982 when heroin users in California displayed Parkinson's-like symptoms after using MPPP contaminated with MPTP. The patients, who were rigid and almost completely immobile, responded to levodopa treatment. No remission of the Parkinson's-like symptoms was reported, suggesting irreversible death of the dopaminergic neurons.[56] The proposed mechanism of MPTP involves disruption of mitochondrial function, including disruption of metabolism and creation of free radicals.[57]

Soon after, MPTP was tested in animal models for its efficacy in inducing Parkinson's disease (with success). MPTP induced akinesia, rigidity, and tremor in primates, and its neurotoxicity was found to be very specific to the substantia nigra pars compacta.[58] In other animals, such as rodents, the induction of Parkinson's by MPTP is incomplete or requires much higher and frequent doses than in primates. Today, MPTP remains the most favored method to induce Parkinson's disease in animal models.[57][59]

History

[edit]

The substantia nigra was discovered in 1784 by Félix Vicq-d'Azyr,[60] and Samuel Thomas von Sömmerring alluded to this structure in 1791.[61] The differentiation between the substantia nigra pars reticulata and compacta was first proposed by Sano in 1910.[62] In 1963, Oleh Hornykiewicz concluded from his observation that "cell loss in the substantia nigra (of Parkinson's disease patients) could well be the cause of the dopamine deficit in the striatum."[63]

Additional images

[edit]
  • Dopamine and serotonin
    Dopamine and serotonin
  • Degradation of substantia nigra associated with Parkinson's disease.
    Degradation of substantia nigra associated with Parkinson's disease.
  • Horizontal MRI (T1 weighted) slice with highlighting indicating location of the substantia nigra.
    Horizontal MRI (T1 weighted) slice with highlighting indicating location of the substantia nigra.
  • Enhanced Neuromelanin MRI with Color images (RGB) showing Substantia nigra pars compacta
    Enhanced Neuromelanin MRI with Color images (RGB) showing Substantia nigra pars compacta
  • Microfilming
    Microfilming

References

[edit]
  1. ^ Rabey JM, Hefti F (1990). "Neuromelanin synthesis in rat and human substantia nigra". Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 2 (1): 1–14. doi:10.1007/BF02251241. PMID 2357268. S2CID 6769760.
  2. ^ Kim SJ, Sung JY, Um JW, Hattori N, Mizuno Y, Tanaka K, Paik SR, Kim J, Chung KC (October 2003). "Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain". The Journal of Biological Chemistry. 278 (43): 41890–9. doi:10.1074/jbc.M306017200. PMID 12917442.
  3. ^ Bolam, J. P.; Brown, M. T. C.; Moss, J.; Magill, P. J. (1 January 2009), "Basal Ganglia: Internal Organization", in Squire, Larry R. (ed.), Encyclopedia of Neuroscience, Oxford: Academic Press, pp. 97–104, doi:10.1016/b978-008045046-9.01294-8, ISBN 978-0-08-045046-9, retrieved 7 September 2020
  4. ^ Kita H, Jaeger D (2016). "Organization of the Globus Pallidus". Handbook of Basal Ganglia Structure and Function, Second Edition. Handbook of Behavioral Neuroscience. Vol. 24. pp. 259–276. doi:10.1016/B978-0-12-802206-1.00013-1. ISBN 9780128022061.
  5. ^ Correa, M; Mingote, S; Betz, A; Wisniecki, A; Salamone, J.D (July 2003). "Substantia nigra pars reticulata GABA is involved in the regulation of operant lever pressing: pharmacological and microdialysis studies". Neuroscience. 119 (3): 759–766. doi:10.1016/s0306-4522(03)00117-9. ISSN 0306-4522. PMID 12809696.
  6. ^ a b Zhou, F.-M.; Lee, C.R. (December 2011). "Intrinsic and integrative properties of substantia nigra pars reticulata neurons". Neuroscience. 198: 69–94. doi:10.1016/j.neuroscience.2011.07.061. ISSN 0306-4522. PMC 3221915. PMID 21839148.
  7. ^ Nauta HJ, Cole M (July 1978). "Efferent projections of the subthalamic nucleus: an autoradiographic study in monkey and cat". The Journal of Comparative Neurology. 180 (1): 1–16. doi:10.1002/cne.901800102. PMID 418083. S2CID 43046462.
  8. ^ Carpenter MB, Nakano K, Kim R (February 1976). "Nigrothalamic projections in the monkey demonstrated by autoradiographic technics". The Journal of Comparative Neurology. 165 (4): 401–15. doi:10.1002/cne.901650402. PMID 57125. S2CID 11790266.
  9. ^ Deniau JM, Kitai ST, Donoghue JP, Grofova I (1982). "Neuronal interactions in the substantia nigra pars reticulata through axon collaterals of the projection neurons. An electrophysiological and morphological study". Experimental Brain Research. 47 (1): 105–13. doi:10.1007/BF00235891. PMID 6288427. S2CID 20289802.
  10. ^ Nicola SM, Surmeier J, Malenka RC (2000). "Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens". Annual Review of Neuroscience. 23: 185–215. doi:10.1146/annurev.neuro.23.1.185. PMID 10845063.
  11. ^ Gernert M, Fedrowitz M, Wlaz P, Löscher W (November 2004). "Subregional changes in discharge rate, pattern, and drug sensitivity of putative GABAergic nigral neurons in the kindling model of epilepsy". The European Journal of Neuroscience. 20 (9): 2377–86. doi:10.1111/j.1460-9568.2004.03699.x. PMID 15525279. S2CID 24485657.
  12. ^ Sato M, Hikosaka O (March 2002). "Role of primate substantia nigra pars reticulata in reward-oriented saccadic eye movement". The Journal of Neuroscience. 22 (6): 2363–73. doi:10.1523/JNEUROSCI.22-06-02363.2002. PMC 6758246. PMID 11896175.
  13. ^ Zahr NM, Martin LP, Waszczak BL (November 2004). "Subthalamic nucleus lesions alter basal and dopamine agonist stimulated electrophysiological output from the rat basal ganglia". Synapse. 54 (2): 119–28. doi:10.1002/syn.20064. PMID 15352137. S2CID 10239473.
  14. ^ Hikosaka O, Wurtz RH (May 1983). "Visual and oculomotor functions of monkey substantia nigra pars reticulata. III. Memory-contingent visual and saccade responses". Journal of Neurophysiology. 49 (5): 1268–84. doi:10.1152/jn.1983.49.5.1268. PMID 6864250.
  15. ^ Tseng KY, Riquelme LA, Belforte JE, Pazo JH, Murer MG (January 2000). "Substantia nigra pars reticulata units in 6-hydroxydopamine-lesioned rats: responses to striatal D2 dopamine receptor stimulation and subthalamic lesions". The European Journal of Neuroscience. 12 (1): 247–56. doi:10.1046/j.1460-9568.2000.00910.x. hdl:11336/39220. PMID 10651879. S2CID 22886675.
  16. ^ Deransart C, Hellwig B, Heupel-Reuter M, Léger JF, Heck D, Lücking CH (December 2003). "Single-unit analysis of substantia nigra pars reticulata neurons in freely behaving rats with genetic absence epilepsy". Epilepsia. 44 (12): 1513–20. doi:10.1111/j.0013-9580.2003.26603.x. PMID 14636321. S2CID 6661257.
  17. ^ Hodge GK, Butcher LL (August 1980). "Pars compacta of the substantia nigra modulates motor activity but is not involved importantly in regulating food and water intake". Naunyn-Schmiedeberg's Archives of Pharmacology. 313 (1): 51–67. doi:10.1007/BF00505805. PMID 7207636. S2CID 24642979.
  18. ^ Pioli EY, Meissner W, Sohr R, Gross CE, Bezard E, Bioulac BH (June 2008). "Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats". Neuroscience. 153 (4): 1213–24. doi:10.1016/j.neuroscience.2008.01.084. PMID 18455318. S2CID 11239586.
  19. ^ a b Ljungberg T, Apicella P, Schultz W (January 1992). "Responses of monkey dopamine neurons during learning of behavioral reactions". Journal of Neurophysiology. 67 (1): 145–63. doi:10.1152/jn.1992.67.1.145. PMID 1552316. S2CID 18024404.
  20. ^ Da Cunha C, Silva MH, Wietzikoski S, Wietzikoski EC, Ferro MM, Kouzmine I, Canteras NS (December 2006). "Place learning strategy of substantia nigra pars compacta-lesioned rats". Behavioral Neuroscience. 120 (6): 1279–84. doi:10.1037/0735-7044.120.6.1279. PMID 17201473.
  21. ^ Da Cunha C, Wietzikoski S, Wietzikoski EC, Miyoshi E, Ferro MM, Anselmo-Franci JA, Canteras NS (May 2003). "Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memory system". Neurobiology of Learning and Memory. 79 (3): 236–42. doi:10.1016/S1074-7427(03)00008-X. PMID 12676522. S2CID 12045200.
  22. ^ Matell MS, Meck WH (January 2000). "Neuropsychological mechanisms of interval timing behavior". BioEssays. 22 (1): 94–103. doi:10.1002/(SICI)1521-1878(200001)22:1<94::AID-BIES14>3.0.CO;2-E. PMID 10649295.
  23. ^ Lima MM, Andersen ML, Reksidler AB, Vital MA, Tufik S (June 2007). Brosnan S (ed.). "The role of the substantia nigra pars compacta in regulating sleep patterns in rats". PLOS ONE. 2 (6): e513. Bibcode:2007PLoSO...2..513L. doi:10.1371/journal.pone.0000513. PMC 1876809. PMID 17551593. Open access icon
  24. ^ Dzirasa K, Ribeiro S, Costa R, Santos LM, Lin SC, Grosmark A, Sotnikova TD, Gainetdinov RR, Caron MG, Nicolelis MA (October 2006). "Dopaminergic control of sleep-wake states". The Journal of Neuroscience. 26 (41): 10577–89. doi:10.1523/JNEUROSCI.1767-06.2006. PMC 6674686. PMID 17035544.
  25. ^ Bejjani, Boulos-Paul; Damier, Philippe; Arnulf, Isabelle; Thivard, Lionel; Bonnet, Anne-Marie; Dormont, Didier; Cornu, Philippe; Pidoux, Bernard; Samson, Yves; Agid, Yves (13 May 1999). "Transient Acute Depression Induced by High-Frequency Deep-Brain Stimulation". New England Journal of Medicine. 340 (19): 1476–1480. doi:10.1056/NEJM199905133401905. ISSN 0028-4793. PMID 10320386.
  26. ^ Jankovic J (April 2008). "Parkinson's disease: clinical features and diagnosis". Journal of Neurology, Neurosurgery, and Psychiatry. 79 (4): 368–76. doi:10.1136/jnnp.2007.131045. PMID 18344392.
  27. ^ Adler CH (2005). "Nonmotor complications in Parkinson's disease". Movement Disorders. 20 (Suppl 11): S23-9. doi:10.1002/mds.20460. PMID 15822106. S2CID 19045599.
  28. ^ Dawson TM, Dawson VL (October 2003). "Molecular pathways of neurodegeneration in Parkinson's disease". Science. 302 (5646): 819–22. Bibcode:2003Sci...302..819D. doi:10.1126/science.1087753. PMID 14593166. S2CID 35486083.
  29. ^ Liang CL, Sinton CM, Sonsalla PK, German DC (December 1996). "Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration". Neurodegeneration. 5 (4): 313–8. doi:10.1006/neur.1996.0042. PMID 9117542.
  30. ^ Grosch J, Winkler J, Kohl Z (2016). "Early Degeneration of Both Dopaminergic and Serotonergic Axons – A Common Mechanism in Parkinson's Disease". Front. Cell. Neurosci. 10: 293. doi:10.3389/fncel.2016.00293. PMC 5177648. PMID 28066188.
  31. ^ Interview. Yoland Smith, PhD[verification needed]
  32. ^ Menke RA, Jbabdi S, Miller KL, Matthews PM, Zarei M (October 2010). "Connectivity-based segmentation of the substantia nigra in human and its implications in Parkinson's disease". NeuroImage. 52 (4): 1175–80. doi:10.1016/j.neuroimage.2010.05.086. PMID 20677376. S2CID 19871414.
  33. ^ Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell. 2019 Dec;18(6):e13031. doi: 10.1111/acel.13031. Epub 2019 Aug 20. Review. PMID 31432604
  34. ^ a b Schaser AJ, Osterberg VR, Dent SE, Stackhouse TL, Wakeham CM, Boutros SW, Weston LJ, Owen N, Weissman TA, Luna E, Raber J, Luk KC, McCullough AK, Woltjer RL, Unni VK. Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders. Sci Rep. 2019 Jul 29;9(1):10919. doi: 10.1038/s41598-019-47227-z. PMID 31358782
  35. ^ Berg, Stacie Z.; Berg, Jonathan (29 September 2023). "Melanin: a unifying theory of disease as exemplified by Parkinson's, Alzheimer's, and Lewy body dementia". Frontiers in Immunology. 14. doi:10.3389/fimmu.2023.1228530. ISSN 1664-3224. PMC 10570809. PMID 37841274.
  36. ^ Gordon, Richard; Albornoz, Eduardo A.; Christie, Daniel C.; Langley, Monica R.; Kumar, Vinod; Mantovani, Susanna; Robertson, Avril A. B.; Butler, Mark S.; Rowe, Dominic B.; O’Neill, Luke A.; Kanthasamy, Anumantha G.; Schroder, Kate; Cooper, Matthew A.; Woodruff, Trent M. (31 October 2018). "Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice". Science Translational Medicine. 10 (465). doi:10.1126/scitranslmed.aah4066. ISSN 1946-6234. PMC 6483075. PMID 30381407.
  37. ^ Li, Jingyi; Zhao, Jingwei; Chen, Longmin; Gao, Hongling; Zhang, Jing; Wang, Danlei; Zou, Yuan; Qin, Qixiong; Qu, Yi; Li, Jiangting; Xiong, Yongjie; Min, Zhe; Yan, Manli; Mao, Zhijuan; Xue, Zheng (1 February 2023). "α-Synuclein induces Th17 differentiation and impairs the function and stability of Tregs by promoting RORC transcription in Parkinson's disease". Brain, Behavior, and Immunity. 108: 32–44. doi:10.1016/j.bbi.2022.10.023. ISSN 0889-1591. PMID 36343753.
  38. ^ van Rossum J (1967). "The significance of dopamine-receptor blockade for the action of neuroleptic drugs". In Brill H, Cole J, Deniker P, Hippius H, Bradley PB (eds.). Neuropsychopharmacology, Proceedings Fifth Collegium Internationale Neuropsychopharmacologicum. pp. 321–9. OCLC 458719.
  39. ^ Kolomeets NS, Uranova NA (1999). "Synaptic contacts in schizophrenia: studies using immunocytochemical identification of dopaminergic neurons". Neuroscience and Behavioral Physiology. 29 (2): 217–21. doi:10.1007/BF02465329. PMID 10432512. S2CID 2233617.
  40. ^ Kumamoto N, Matsuzaki S, Inoue K, Hattori T, Shimizu S, Hashimoto R, Yamatodani A, Katayama T, Tohyama M (June 2006). "Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin". Biochemical and Biophysical Research Communications. 345 (2): 904–9. doi:10.1016/j.bbrc.2006.04.163. PMID 16701550.
  41. ^ Shibata E, Sasaki M, Tohyama K, Otsuka K, Endoh J, Terayama Y, Sakai A (September 2008). "Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus". Biological Psychiatry. 64 (5): 401–6. doi:10.1016/j.biopsych.2008.03.021. PMID 18452894. S2CID 25752976.
  42. ^ Pergolizzi, Joseph V.; Webster, Lynn R.; Vortsman, Eugene; Ann LeQuang, Jo; Raffa, Robert B. (December 2021). "Wooden Chest syndrome: The atypical pharmacology of fentanyl overdose". Journal of Clinical Pharmacy and Therapeutics. 46 (6): 1505–1508. doi:10.1111/jcpt.13484. ISSN 0269-4727. PMID 34240442.
  43. ^ Baruah, Udismita; Gaur, Himanshu; Saigal, Deepti; Pandey, Dimple (December 2022). "Wooden chest syndrome: A curious case of fentanyl induced rigidity in adults". Indian Journal of Anaesthesia. 66 (12): 881–882. doi:10.4103/ija.ija_171_22. ISSN 0019-5049. PMC 9842087. PMID 36654889.
  44. ^ Rosal, Nathaniel R.; Thelmo, Franklin L.; Tzarnas, Stephanie; DiCalvo, Lauren; Tariq, Shafaq; Grossman, Craig (January 2021). "Wooden Chest Syndrome: A Case Report of Fentanyl-Induced Chest Wall Rigidity". Journal of Investigative Medicine High Impact Case Reports. 9: 232470962110340. doi:10.1177/23247096211034036. ISSN 2324-7096. PMC 8312149. PMID 34301155.
  45. ^ a b c d e Miller GM (January 2011). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry. 116 (2): 164–76. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.
  46. ^ "Amphetamine". DrugBank. University of Alberta. 8 February 2013. Retrieved 13 October 2013.
  47. ^ a b c Eiden LE, Weihe E (January 2011). "VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse". Annals of the New York Academy of Sciences. 1216 (1): 86–98. Bibcode:2011NYASA1216...86E. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197. PMID 21272013.
  48. ^ Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR, Davenport AP (March 2009). "International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature". Pharmacological Reviews. 61 (1): 1–8. doi:10.1124/pr.109.001107. PMC 2830119. PMID 19325074.
  49. ^ Heikkila RE, Cabbat FS, Duvoisin RC (1979). "Motor activity and rotational behavior after analogs of cocaine: correlation with dopamine uptake blockade". Communications in Psychopharmacology. 3 (5): 285–90. PMID 575770.
  50. ^ Lakoski JM, Galloway MP, White FJ (1991). Cocaine. Telford Press. ISBN 978-0-8493-8813-2.
  51. ^ Lacey MG, Mercuri NB, North RA (April 1990). "Actions of cocaine on rat dopaminergic neurones in vitro". British Journal of Pharmacology. 99 (4): 731–5. doi:10.1111/j.1476-5381.1990.tb12998.x. PMC 1917549. PMID 2361170.
  52. ^ a b Xia Y, Goebel DJ, Kapatos G, Bannon MJ (September 1992). "Quantitation of rat dopamine transporter mRNA: effects of cocaine treatment and withdrawal". Journal of Neurochemistry. 59 (3): 1179–82. doi:10.1111/j.1471-4159.1992.tb08365.x. PMID 1494906. S2CID 34068876.
  53. ^ See RE, Elliott JC, Feltenstein MW (October 2007). "The role of dorsal vs ventral striatal pathways in cocaine-seeking behavior after prolonged abstinence in rats". Psychopharmacology. 194 (3): 321–31. doi:10.1007/s00213-007-0850-8. PMID 17589830. S2CID 12652533.
  54. ^ Cheng N, Maeda T, Kume T, Kaneko S, Kochiyama H, Akaike A, Goshima Y, Misu Y (December 1996). "Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons". Brain Research. 743 (1–2): 278–83. doi:10.1016/S0006-8993(96)01056-6. PMID 9017256. S2CID 22529926.
  55. ^ Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003). "Limitations of current Parkinson's disease therapy". Annals of Neurology. 53 (Suppl 3): S3–12, discussion S12–5. doi:10.1002/ana.10513. PMID 12666094. S2CID 45078589.
  56. ^ Langston JW, Ballard P, Tetrud JW, Irwin I (February 1983). "Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis". Science. 219 (4587): 979–80. Bibcode:1983Sci...219..979L. doi:10.1126/science.6823561. PMID 6823561. S2CID 31966839.
  57. ^ a b Schmidt N, Ferger B (2001). "Neurochemical findings in the MPTP model of Parkinson's disease". Journal of Neural Transmission. 108 (11): 1263–82. doi:10.1007/s007020100004. PMID 11768626. S2CID 2834254.
  58. ^ Langston JW, Forno LS, Rebert CS, Irwin I (February 1984). "Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey". Brain Research. 292 (2): 390–4. doi:10.1016/0006-8993(84)90777-7. PMID 6607092. S2CID 34183578.
  59. ^ Blanchet PJ, Calon F, Morissette M, Hadj Tahar A, Bélanger N, Samadi P, Grondin R, Grégoire L, Meltzer L, Di Paolo T, Bédard PJ (July 2004). "Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms". Parkinsonism & Related Disorders. 10 (5): 297–304. doi:10.1016/j.parkreldis.2004.02.011. PMID 15196509.
  60. ^ Tubbs RS, Loukas M, Shoja MM, Mortazavi MM, Cohen-Gadol AA (July 2011). "Félix Vicq d'Azyr (1746-1794): early founder of neuroanatomy and royal French physician". Child's Nervous System. 27 (7): 1031–4. doi:10.1007/s00381-011-1424-y. PMID 21445631.
  61. ^ Swanson LW (2014). Neuroanatomical terminology : a lexicon of classical origins and historical foundations. England: Oxford University Press. ISBN 9780195340624.
  62. ^ Sano T (1910). "Beitrag zur vergleichenden Anatomie der Substantia nigra, des Corpus Luysii und der Zona incerta". MSCHR Psychiat Neurol. 28 (1): 26–34. doi:10.1159/000209678.
  63. ^ Hornykiewicz, O. (2006). "The discovery of dopamine deficiency in the parkinsonian brain". In Riederer, P.; Reichmann, H.; Youdim, M. B. H.; Gerlach, M. (eds.). Parkinson's Disease and Related Disorders. Springer Vienna. pp. 9–15. doi:10.1007/978-3-211-45295-0_3. ISBN 978-3-211-28927-3. PMID 17017502. {{cite book}}: |journal= ignored (help)
[edit]
Wikimedia Commons has media related to Substantia nigra.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Substantia_nigra&oldid=1254977094"